Trends in the Clinical Presentation of Primary Rhegmatogenous Retinal Detachments During the First Year of the COVID-19 Pandemic.

Am J Ophthalmol

From the Department of Ophthalmology & Visual Neurosciences, University of Minnesota Medical School (R.M., J.M.K., E.H.R., P.H.T.); College of Biological Sciences, University of Minnesota, - Twin Cities (A.V.); and Vitreo Retinal Surgery, P.L.L.C., (G.S.S., P.J.B., E.H.R., P.H.T.), Minneapolis, Minnesota, USA. Electronic address:

Published: May 2022

AI Article Synopsis

  • The study evaluated how the COVID-19 pandemic affected the clinical presentation of acute, primary rhegmatogenous retinal detachment (RRD) over a year.
  • A comparison was made between patients treated during the pandemic and those from the previous year, with significant findings indicating a higher proportion of severe cases (mac-off RRD) and worse visual acuity in the pandemic group.
  • Results showed increased prevalence of primary proliferative vitreoretinopathy and higher follow-up loss rates among pandemic cohort patients, highlighting the pandemic's impact on patient care.

Article Abstract

Purpose: To evaluate the effect of 1 full year of the coronavirus disease 2019 (COVID-19) pandemic on clinical presentation of acute, primary rhegmatogenous retinal detachment (RRD).

Design: Single-center, retrospective observational cohort study.

Methods: Patients were divided into 2 cohorts: consecutive patients treated for primary RRD during the COVID-19 pandemic (March 9, 2020, to March 7, 2021; pandemic cohort) and patients treated during the corresponding time in previous year (March 11, 2019, to March 8, 2020; control cohort).

Main Outcome Measures: Proportion of patients presenting with macula-involving (mac-off) or macula-sparring (mac-on) RRD.

Results: A total of 952 patients in the pandemic cohort and 872 patients in the control cohort were included. Demographic factors were similar. Compared with the control cohort, a significantly greater number of pandemic cohort patients presented with mac-off RRDs ([60.92%] pandemic, [48.17%] control, P = .0001) and primary proliferative vitreoretinopathy ([15.53%] pandemic, [6.9%] control, P = .0001). Pandemic cohort patients (10.81%) had significantly higher rates of lost to follow-up compared with the control cohort (4.43%; P = .0001). Patients new to our clinic demonstrated a significant increase in mac-off RRDs in the pandemic cohort (65.35%) compared with the control cohort (50.40%; P = .0001). Pandemic cohort patients showed worse median final best-corrected visual acuity (0.30 logarithm of the minimum angle of resolution) compared with the control cohort (0.18 logarithm of the minimum angle of resolution; P = .0001).

Conclusions: Patients with primary RRD during the first year of the COVID-19 pandemic were more likely to have mac-off disease, present with primary proliferative vitreoretinopathy, be lost to follow-up, and have worse final best-corrected visual acuity outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603252PMC
http://dx.doi.org/10.1016/j.ajo.2021.11.017DOI Listing

Publication Analysis

Top Keywords

pandemic cohort
24
control cohort
20
covid-19 pandemic
16
cohort patients
16
compared control
16
pandemic
12
cohort
12
patients
11
clinical presentation
8
primary rhegmatogenous
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!